Subscribe
shutterstock_742316485_chrisdorney
chrisdorney / Shutterstock.com
5 March 2020AmericasRory O'Neill

Gilead to face HIV antitrust claims

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?